Crucially, future trial designs must incorporate dormancy-specific endpoints, such as time-to-reactivation, and stratify patients by BC subtype (e.g., ER+ versus TNBC) to effectively address inherent heterogeneity and optimize therapeutic strategies [268]. This evidence concerns the gene ESR1 and breast cancer.